The effect of different desolvating agents on BSA nanoparticle properties and encapsulation of curcumin

Sadeghi, Rohollah; Moosavi-Movahedi, Ali Akbar; Emamjomeh, Z; Kalbasi, Ahmad; Razavi, Shabnam; Karimi, Majid; Kokini, Jozef L.

doi:10.1007/s11051-014-2565-1

Cited by 90 publications

(59 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thereby, particles around 125 nm tend to increase in particle size after resuspension. This is in line with results from other research groups, which also showed that the particle size could be reduced by sonication afterwards [43, 44]. Sadeghi et al also pointed out that only a few nanoparticles showed aggregation after resuspension, which provoked the measured increase in particle size [43].…”

Section: Discussionsupporting

confidence: 90%

Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration

et al. 2016

View full text Add to dashboard Cite

Since therapeutic peptides and oligonucleotides are gathering interests as active pharmaceutical ingredients (APIs), nanoparticulate drug delivery systems are becoming of great importance. Thereby, the possibility to design drug delivery systems according to the therapeutic needs of APIs enhances clinical implementation. Over the last years, the focus of our group was laid on protamine-oligonucleotide-nanoparticles (so called proticles), however, the possibility to modify the size, zeta potential or loading efficiencies was limited. Therefore, at the present study we integrated a stepwise addition of protamine (titration) into the formation process of proticles loaded with the angiogenic neuropeptide secretoneurin (SN). A particle size around 130 nm was determined when proticles were assembled by the commonly used protamine addition at once. Through application of the protamine titration process it was possible to modify and adjust the particle size between approx. 120 and 1200 nm (dependent on mass ratio) without influencing the SN loading capacity. Dynamic light scattering pointed out that the difference in particle size was most probably the result of a secondary aggregation. Initially-formed particles of early stages in the titration process aggregated towards bigger assemblies. Atomic-force-microscopy images also revealed differences in morphology along with different particle size. In contrast, the SN loading was only influenced by the applied mass ratio, where a slight saturation effect was observable. Up to 65% of deployed SN could be imbedded into the proticle matrix. An in-vivo biodistribution study (i.m.) showed a retarded distribution of SN from the site of injection after the application of a SN-proticle formulation. Further, it was demonstrated that SN loaded proticles can be successfully freeze-dried and resuspended afterwards. To conclude, the integration of the protamine titration process offers new possibilities for the formulation of proticles in order to address key parameters of drug delivery systems as size, API loading or modified drug release.

show abstract

Section: Discussionsupporting

confidence: 90%

Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The cross‐linking treatment with glutaraldehyde tightens the structure of nanoparticles and they can maintain their size and shape for a long time. Sadeghi and others () also reported preparation of stable BSA and curcumin‐loaded BSA for 1 mo in aqueous media (deionized water). The stability of nanoparticles is one of the necessary requirements for the nanoparticle production method to be able to use them in food and pharmaceutical applications.…”

Section: Resultsmentioning

confidence: 99%

Effects of Desolvating Agent Types, Ratios, and Temperature on Size and Nanostructure of Nanoparticles from α‐Lactalbumin and Ovalbumin

Etorki

Gao

Sadeghi

et al. 2016

Journal of Food Science

View full text Add to dashboard Cite

In this study, we compare the preparation of ovalbumin (OVA) and α-lactalbumin (α-LA) nanoparticles using different desolvating agents (ethanol, acetone, and methanol) and water: desolvating agent volume ratios (1:3, 1:4, 1:5, 1:10, and 1:20). Also the effects of protein solution temperature (25, 50, and 80 ℃) on the size of nanoparticles and the stability of crosslinked nanoparticles for 30 d were studied. OVA and α-LA were shown to be good candidates for nanoparticulation and nanoparticles in the range of 60 to 230 nm were obtained. The comparison between the 2 proteins offers guidance to optimize OVA and α-LA nanoparticle fabrication and to efficiently obtain nanoparticles with desired characteristics. The particle sizes of OVA nanoparticles were found to be in the range of 60 to 160 nm, and the particle sizes of α-LA were between 150 and 230 nm. The sizes varied with different desolvating agents: for OVA, ethanol, and methanol both produced nanoparticles smaller than 100 nm; for α-LA, methanol produced the smallest nanoparticles. Water: desolvating agent ratios, in the studied range, did not show a significant effect on the particle sizes for both OVA and α-LA nanoparticles. The size and morphology of the nanoparticles were found to change when the protein solutions were heated up to 50 and 80 ℃ and cooled down before nanoparticulation and most nanoparticles had a smaller diameter.

show abstract

“…Sadeghi et al explained that compared to the use of pure acetone, ethanol, and mixtures of ethanol with acetone resulted in more spherical NPs [57]. Another study used a desolvation method with a membrane contactor for the large-scale production of BSA NPs, with comparable characteristics to particles that were produced by small-scale methods [58].…”

Section: Albumin Nanostructuresmentioning

confidence: 99%

Albumin nanostructures as advanced drug delivery systems

Karimi

Bahrami

Ravari

et al. 2016

Expert Opinion on Drug Delivery

310

190

View full text Add to dashboard Cite

Introduction One of the biggest impacts that the nanotechnology has made on medicine and biology, has been in the area of drug delivery systems (DDSs). Many drugs suffer from serious problems concerning insolubility, instability in biological environments, poor uptake into cells and tissues, suboptimal selectivity for targets and unwanted side effects. Nanocarriers can be designed as DDSs to overcome many of these drawbacks. One of the most versatile building blocks to prepare these nanocarriers is the ubiquitous, readily available and inexpensive protein, serum albumin. Areas covered This review covers the use of different types of albumin (human, bovine, rat, and chicken egg) to prepare nanoparticle and microparticle-based structures to bind drugs. Various methods have been used to modify the albumin structure. A range of targeting ligands can be attached to the albumin that can be recognized by specific cell receptors that are expressed on target cells or tissues. Expert opinion The particular advantages of albumin used in DDSs include ready availability, ease of chemical modification, good biocompatibility, and low immunogenicity. The regulatory approvals that have been received for several albumin-based therapeutic agents suggest that this approach will continue to be successfully explored.

show abstract

The effect of different desolvating agents on BSA nanoparticle properties and encapsulation of curcumin

Cited by 90 publications

References 43 publications

Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration

Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration

Effects of Desolvating Agent Types, Ratios, and Temperature on Size and Nanostructure of Nanoparticles from α‐Lactalbumin and Ovalbumin

Albumin nanostructures as advanced drug delivery systems

Contact Info

Product

Resources

About